orforglipron and retatrutide What is the estimated annual cost of Eli Lilly's next-generation obesity drugs? Retatrutide Approval Date Eli Lilly

Final MRP: 3,200 - 3,800 per month

They slow gastric emptying so food stays in your stomach longer, creating extended feelings of fullness while also sending signals to your brain's appetite centers to reduce hunger cravings between meals

Some patients experience what they describe as a plateau

Tirzepatide, a coagonist of GIPR and GLP-1R, is characterized by greater efficacy in both glucose lowering and weight loss than can be achieved with current selective GLP-1RAs (16), while having a comparable adverse event profile

A 2025 meta-analysis involving 397 women with PCOS revealed that those using GLP-1 agonists for at least 12 weeks lost an average of 7.9 lbs (3.57 kg)

The historical tendency to equate pleiotropy with risk rather than opportunity appears increasingly outdated in light of contemporary successes with multi-agonist and network-based therapies